Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Cue Biopharma, Inc. reported revenue of $27M, up 195.7% year over year. Operating margin was -96.7% and net margin -96.9%, on a free-cash-flow margin of -79.6% with capital expenditure at 0.6% of revenue. Every figure is computed directly from CUE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $27M | -96.7% | -96.9% |
| FY2024 | $9M | -446.9% | -438.0% |
| FY2023 | $5M | -949.9% | -924.1% |
| FY2022 | $1M | -4275.1% | -4257.8% |
| FY2021 | $15M | -292.6% | -295.6% |
How does CUE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.